Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

The onset of heart failure is typically preceded by cardiac hypertrophy, a response of the
heart to increased workload, a cardiac insult such as a heart attack or genetic mutation …

Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been
linked with potentially limiting cardiotoxicity, including emerging reports of profound …

Background: Ibrutinib has revolutionized treatment for several B-cell malignancies.
However, a recent clinical trial where ibrutinib was used in a front-line setting showed …

Protein kinase B (Akt), similar to many other protein kinases, is at the crossroads of cell
death and survival, playing a pivotal role in multiple interconnected cell signaling …

Cardiovascular disease is the primary cause of morbidity and mortality among the diabetic
population. Both experimental and clinical evidence suggest that diabetic subjects are …

The Bruton, s tyrosine kinase (BTK) inhibitor ibrutinib sets a new standard of care for the
treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) 1, 2 and …

Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …

Ibrutinib, a novel and potent Bruton tyrosine kinase inhibitor, is an effective and well-
tolerated treatment for a variety of B-cell lymphomas. However, its use is associated with an …

MicroRNAs are dysregulated in a setting of heart disease and have emerged as promising
therapeutic targets. MicroRNA-34 family members (miR-34a,-34b, and-34c) are up …